本文選題：食管癌 + 根治性放療　； 參考：《山東大學(xué)》2015年碩士論文

【摘要】：研究背景根治性放療或放化療現(xiàn)已是被廣泛認(rèn)可的未手術(shù)食管癌的主要治療方案,然而根治性放療后的多數(shù)病人在1-2年內(nèi)出現(xiàn)復(fù)發(fā)或轉(zhuǎn)移,局部復(fù)發(fā)依然是根治性放療失敗的主要類型。根治性放療后局部復(fù)發(fā)的食管癌患者,治療方案的選擇較為局限,主要是手術(shù)治療或者姑息性化療,一些頭頸部惡性腫瘤的再程放療被證實(shí)是有效的,而關(guān)于食管癌再程放療的文獻(xiàn)資料較少,對(duì)根治性放療后復(fù)發(fā)的患者再次采用放射治療的可行性和有效性仍存爭(zhēng)議。目的觀察研究食管癌根治性放療后局部復(fù)發(fā)的患者行再程放療的近期療效、不良反應(yīng)以及復(fù)發(fā)后生存期,分析影響患者復(fù)發(fā)后生存預(yù)后的各種因素,綜合評(píng)價(jià)食管癌再程放療的可行性和臨床價(jià)值。方法回顧性收集根治性放療或放化療后CR或PR、并在首次治療6個(gè)月以后出現(xiàn)局部復(fù)發(fā)、行再程放療或放化療的52例食管鱗癌患者的臨床資料,根據(jù)其再程放療是否聯(lián)合化療分為單純?cè)俪谭暖?re-RT)組24例和再程放療聯(lián)合化療(RCT)組28例,觀察并比較再程放療或放化療的近期療效、不良反應(yīng),并且分析各臨床病理因素與生存預(yù)后之間的關(guān)系,綜合評(píng)價(jià)根治性放療后復(fù)發(fā)的食管癌行再程放療的臨床價(jià)值。應(yīng)用IBM SPSS Statistics 19.0統(tǒng)計(jì)軟件進(jìn)行統(tǒng)計(jì)處理,組間一般資料、療效及不良反應(yīng)發(fā)生率的比較采用卡方檢驗(yàn),采用Kaplan-Meier法制作全組及各亞組患者的生存曲線并用log-rank檢驗(yàn)方法檢驗(yàn)生存率差異的顯著性水平,應(yīng)用Cox比例風(fēng)險(xiǎn)模型進(jìn)行與復(fù)發(fā)后生存期有關(guān)的單因素以及多因素分析。所有檢驗(yàn)統(tǒng)計(jì)量設(shè)定為p0.05時(shí)具有統(tǒng)計(jì)學(xué)意義。結(jié)果全組患者再程放療后CR者10例(19.2%),PR者26例(50.0%),SD者13例(25.0%),PD者3例(5.8%),有效(CR+PR)者36例(69.2%)。RCT組的有效率(71.4%)略高于re-RT組(58.3%),但差異無統(tǒng)計(jì)學(xué)意義(p=0.331)。全組發(fā)生2-3級(jí)急性放射性食管炎者21例(40.4%),re-RT組9例(37.5%),RCT組12例(42.9%)；2-3級(jí)炎急性放射性肺炎者9例(17.3%),re-RT組3例(12.5%),RCT組6例(21.4%)；2-3度骨髓抑制者21例(40.4%),re-RT組1例(4.2%),RCT組20例(71.4%)；放療中或放療后穿孔6例(11.5%),re-RT組2例(8.3%),RCT組4例(14.3%),放療后狹窄4例(7.7%),re-RT組2例(8.3%),RCT組2例(7.1%),除骨髓抑制發(fā)生率RCT組顯著高于re-RT組外,其余兩組間不良反應(yīng)發(fā)生率的差異無統(tǒng)計(jì)學(xué)意義。全組52例患者中位復(fù)發(fā)后生存期為11個(gè)月(95%CI 9.380-12.630),1年生存率為44.2%,2年生存率為11.5%,3年生存率為3.8%。單因素分析結(jié)果為復(fù)發(fā)間隔時(shí)間在1年以上(p=0.000)、再程放療時(shí)PS評(píng)分0-1分(p=0.000)、再程放療聯(lián)合化療(p=0.045)以及再程放療的劑量"g50Gy(p=0.000)的患者的復(fù)發(fā)后生存預(yù)后相對(duì)較好,多因素分析顯示再程放療時(shí)患者的PS評(píng)分以及再程放療是否聯(lián)合化療是影響患者預(yù)后的獨(dú)立因素。再程放療時(shí)的PS評(píng)分為0-1分者43例,中位生存期是13個(gè)月,1年生存率為53.5%；PS評(píng)分為2-3分者9例,中位生存期是8個(gè)月,1年生存率為11.1%。再程治療方案為re-RT者24例,中位生存期是9個(gè)月,1年生存率為37.5%；再程治療為RCT者28例,中位生存期為12個(gè)月,1年生存率為50.0%。結(jié)論對(duì)于一部分根治性放療后局部復(fù)發(fā)的食管癌患者而言,再程放療是可行的,可以有效控制疾病進(jìn)展并改善生存預(yù)后。患者的預(yù)后與復(fù)發(fā)間隔時(shí)間、再程放療時(shí)的PS評(píng)分、再程放療的劑量以及再程放療是否聯(lián)合化療有關(guān),對(duì)于復(fù)發(fā)時(shí)PS評(píng)分0-1分、復(fù)發(fā)間隔時(shí)間為1年以上的患者,再程放療劑量"g50Gy并聯(lián)合化療可以改善生存預(yù)后。但再程放時(shí)不良反應(yīng)的發(fā)生率較首程放療高且穿孔等嚴(yán)重并發(fā)癥的風(fēng)險(xiǎn)明顯增加,應(yīng)當(dāng)嚴(yán)格篩選病例、謹(jǐn)慎進(jìn)行再程放療前的評(píng)估。
[Abstract]:Background radical radiotherapy or chemoradiotherapy is now a major treatment for widely recognized unoperated esophageal cancer. However, most patients after radical radiotherapy have relapsed or metastases within 1-2 years. Local recurrence is still the main type of radical radiotherapy failure. Patients with locally recurrent esophageal cancer after radical radiotherapy are the treatment regimens. The selection is limited, mainly for surgical treatment or palliative chemotherapy, and recourse radiotherapy in some head and neck malignant tumors is proved to be effective, while the literature on recourse radiotherapy for esophageal cancer is less, and the feasibility and effectiveness of radiotherapy for recurrent patients after radical radiotherapy are still in dispute. The short term effect, adverse reaction and the survival period after recurrent radiotherapy after radical radiotherapy for patients with carcinoma of tube, the factors affecting the survival prognosis of the patients and the feasibility and clinical value of re radiotherapy for esophageal cancer were evaluated comprehensively. Methods CR or PR after radical radiotherapy or radiotherapy were reviewed. 6 months after the treatment, the clinical data of 52 cases of esophageal squamous cell carcinoma with recurrent radiotherapy or radiotherapy and radiotherapy were divided into 24 cases of re-RT group and 28 cases of radiotherapy combined with chemotherapy (RCT). And the relationship between the clinicopathological factors and the survival prognosis was analyzed. The clinical value of recourse radiotherapy for recurrent esophageal cancer after radical radiotherapy was evaluated. IBM SPSS Statistics 19 statistical software was used for statistical processing. The general data, the comparison of the curative effect and the incidence of adverse reaction were compared with the chi square test and the use of Kaplan-Meier The survival curves of the patients in the whole group and the subgroups were made and the significant level of the survival rate difference was tested by log-rank test. The Cox proportional risk model was used to carry out the single factor and multifactor analysis related to the recurrence of the survival period. All the test statistics were set as P0.05. 10 cases (19.2%), 26 cases (50%), 13 cases (25%) of SD, 3 cases (5.8%) of PD, 36 (69.2%).RCT group in CR+PR (69.2%).RCT group (71.4%) was slightly higher than that of re-RT group (58.3%), but the difference was not statistically significant (p=0.331). There were 9 cases (17.3%) with acute radiation pneumonitis, 3 cases in group re-RT (12.5%), 6 cases in group RCT (21.4%), 21 (40.4%) in 2-3 degree myelosuppressor, 1 in group re-RT (4.2%), 3 in group RCT, 3 in radiotherapy or after radiotherapy, in group RCT, re-RT group, RCT group, except bone marrow The incidence of inhibition in the RCT group was significantly higher than that in the re-RT group. There was no significant difference in the incidence of adverse reactions among the other two groups. The 52 patients in the whole group had a 11 month survival period (95%CI 9.380-12.630), the 1 year survival rate was 44.2%, the 2 year survival rate was 11.5%, and the 3 year survival rate was 3.8%. single factor analysis for 1 years for the recurrence interval of 1 years. P=0.000, PS score 0-1 (p=0.000), RRT combined with chemotherapy (p=0.045) and the recurrence of g50Gy (p=0.000) in re radiotherapy were relatively good for the survival prognosis. Multivariate analysis showed that the PS score of the patients and the combined chemotherapy of re radiotherapy were independent factors affecting the prognosis of the patients. The PS score was 0-1 in 43, with a median survival period of 13 months and 53.5% for 1 years, 9 with a PS score of 2-3, a median survival of 8 months, and 24 for re-RT in the 1 year survival rate of 11.1%., the median survival time was 9 months, the 1 year survival rate was 37.5%; The 2 month, 1 year survival rate is 50.0%. conclusion for some patients with locally recurrent esophageal cancer after radical radiotherapy. Reprocess radiotherapy is feasible. It can effectively control the progression of the disease and improve the survival prognosis. The prognosis and interval time of the patients, the PS score in the recourse radiotherapy, the dose of the re course radiotherapy, and the combination of the re radiotherapy. Chemotherapy is associated with a recurrent PS score of 0-1 and a recurrent interval of more than 1 years. "G50Gy combined with chemotherapy can improve survival prognosis. But the incidence of adverse reactions is significantly higher than the risk of severe complications such as high first course radiotherapy and perforation. Evaluation before radiotherapy.
【學(xué)位授予單位】：山東大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2015
【分類號(hào)】：R735.1

【參考文獻(xiàn)】

相關(guān)期刊論文 前3條

1 賈麗;王仁本;于金明;孟繁會(huì);郭英華;李金麗;朱昆莉;;食管癌放療后復(fù)發(fā)的再放療32例療效觀察[J];中華腫瘤防治雜志;2006年11期

2 張清琴;王軍民;楊萌;王犖楠;崔艷慧;李小瑞;靳彩玲;;替吉奧聯(lián)合調(diào)強(qiáng)放療對(duì)食管癌再程放療的療效觀察[J];山東醫(yī)藥;2015年01期

3 宋美芳,邱灝,王國(guó)民;27例食管癌放療后復(fù)發(fā)的再放療療效分析[J];中國(guó)癌癥雜志;2000年05期

，

本文編號(hào)：1917287